Back to Search
Start Over
Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: From lab to clinic
- Source :
- Critical Reviews in Oncology/Hematology. 61:52-69
- Publication Year :
- 2007
- Publisher :
- Elsevier BV, 2007.
-
Abstract
- Most solid tumors express the cyclooxygenase-2 (COX-2) protein, a target of NSAIDs. COX-2 overexpression in tumorsis considered a predictor of more advanced stage disease and of worse prognosis in a number of studies investigating solid malignancies. Therefore, NSAIDs are evaluated as anti-cancer drugs. NSAIDs inhibit proliferation, invasiveness of tumors, and angiogenesis and overcome apoptosis resistance in a COX-2 dependent and independent manner. This review will focus on the rationale behind NSAIDs, including selective COX-2 inhibitors, in combination with conventional chemotherapeutic drugs or novel molecular targeted drugs. Studies investigating anti-cancer effects of NSAIDs on cell lines and xenograft models have shown modulation of the Akt, NF-kappa B, tyrosine kinase and the death receptor-mediated apoptosis pathways. COX-2 expression in tumors is not yet used as biomarker in the clinic. Despite the increased risk on cardiovascular toxicity induced by selective COX-2 inhibitors, several ongoing clinical trials are still investigating the therapeutic benefits of NSAIDs in oncology. The anti-tumor effects in these trials balanced with the side effects data will define the precise role of selective COX-2 inhibitors in the treatment of cancer patients. (c) 2006 Elsevier Ireland Ltd. All rights reserved.
- Subjects :
- NSAIDs
HUMAN BREAST-CANCER
Angiogenesis
CELL LUNG-CANCER
medicine.medical_treatment
NF-KAPPA-B
Antineoplastic Agents
ACUTE MYELOID-LEUKEMIA
Pharmacology
chemotherapy
Pharmacotherapy
Humans
Medicine
SELECTIVE CYCLOOXYGENASE-2 INHIBITOR
CELECOXIB INDUCES APOPTOSIS
Protein kinase B
Chemotherapy
Cyclooxygenase 2 Inhibitors
business.industry
NEGATIVE PROGNOSTIC-FACTOR
Anti-Inflammatory Agents, Non-Steroidal
Cancer
Drug Synergism
Hematology
medicine.disease
cyclooxygenase
Clinical trial
HUMAN GASTRIC-CARCINOMA
Oncology
ENDOTHELIAL GROWTH-FACTOR
Cancer research
Biomarker (medicine)
Drug Therapy, Combination
business
Tyrosine kinase
COLORECTAL-CARCINOMA CELLS
Subjects
Details
- ISSN :
- 10408428
- Volume :
- 61
- Database :
- OpenAIRE
- Journal :
- Critical Reviews in Oncology/Hematology
- Accession number :
- edsair.doi.dedup.....63df9a382b84d50ce8fb648cc453ccf8